5,408 Shares in Johnson & Johnson $JNJ Acquired by Precision Wealth Strategies LLC

Precision Wealth Strategies LLC acquired a new position in Johnson & Johnson (NYSE:JNJ) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 5,408 shares of the company’s stock, valued at approximately $826,000.

A number of other hedge funds also recently added to or reduced their stakes in the company. USA Financial Formulas raised its holdings in Johnson & Johnson by 19.2% in the 2nd quarter. USA Financial Formulas now owns 1,709 shares of the company’s stock worth $261,000 after acquiring an additional 275 shares during the last quarter. Founders Capital Management raised its stake in Johnson & Johnson by 35.4% during the 2nd quarter. Founders Capital Management now owns 47,330 shares of the company’s stock valued at $7,230,000 after buying an additional 12,380 shares during the last quarter. Parkwoods Wealth Partners LLC raised its stake in Johnson & Johnson by 5.6% during the 2nd quarter. Parkwoods Wealth Partners LLC now owns 1,630 shares of the company’s stock valued at $249,000 after buying an additional 87 shares during the last quarter. First Pacific Financial raised its stake in Johnson & Johnson by 1,139.2% during the 2nd quarter. First Pacific Financial now owns 19,133 shares of the company’s stock valued at $2,923,000 after buying an additional 17,589 shares during the last quarter. Finally, Trilogy Capital Inc. raised its stake in Johnson & Johnson by 7.1% during the 2nd quarter. Trilogy Capital Inc. now owns 5,624 shares of the company’s stock valued at $859,000 after buying an additional 372 shares during the last quarter. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the stock. Bank of America boosted their target price on shares of Johnson & Johnson from $161.00 to $175.00 and gave the company a “neutral” rating in a research note on Thursday, July 17th. Wall Street Zen upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating in a research note on Saturday, September 13th. Morgan Stanley boosted their target price on shares of Johnson & Johnson from $171.00 to $176.00 and gave the company an “equal weight” rating in a research note on Thursday, July 17th. JPMorgan Chase & Co. boosted their target price on shares of Johnson & Johnson from $185.00 to $200.00 and gave the company a “neutral” rating in a research note on Tuesday, September 16th. Finally, Guggenheim upgraded shares of Johnson & Johnson from a “neutral” rating to a “buy” rating and boosted their target price for the company from $167.00 to $206.00 in a research note on Tuesday, September 23rd. Two investment analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and nine have given a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $181.40.

Johnson & Johnson Trading Down 0.0%

NYSE:JNJ opened at $185.98 on Friday. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76. The firm has a market capitalization of $447.91 billion, a price-to-earnings ratio of 19.89, a price-to-earnings-growth ratio of 2.37 and a beta of 0.40. Johnson & Johnson has a one year low of $140.68 and a one year high of $186.59. The business has a fifty day moving average price of $175.78 and a 200-day moving average price of $162.66.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, topping the consensus estimate of $2.68 by $0.09. The firm had revenue of $23.74 billion during the quarter, compared to analyst estimates of $22.85 billion. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.Johnson & Johnson’s revenue was up 5.8% on a year-over-year basis. During the same period in the prior year, the business posted $2.82 EPS. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. Sell-side analysts forecast that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th were issued a $1.30 dividend. The ex-dividend date of this dividend was Tuesday, August 26th. This represents a $5.20 annualized dividend and a yield of 2.8%. Johnson & Johnson’s dividend payout ratio is currently 55.61%.

Insiders Place Their Bets

In related news, EVP Jennifer L. Taubert sold 56,471 shares of the company’s stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the transaction, the executive vice president owned 178,013 shares of the company’s stock, valued at approximately $31,652,491.53. This represents a 24.08% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Corporate insiders own 0.16% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.